Press coverage about Heat Biologics (NASDAQ:HTBX) has trended positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Heat Biologics earned a news sentiment score of 0.36 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
Heat Biologics (NASDAQ:HTBX) traded down 0.8234% during midday trading on Wednesday, reaching $0.5902. The company’s stock had a trading volume of 149,576 shares. The company’s market cap is $21.02 million. The stock has a 50-day moving average price of $0.69 and a 200 day moving average price of $0.84. Heat Biologics has a 12 month low of $0.55 and a 12 month high of $3.35.
Heat Biologics (NASDAQ:HTBX) last announced its quarterly earnings data on Friday, March 31st. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.05. The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.13 million. Analysts expect that Heat Biologics will post ($0.40) earnings per share for the current fiscal year.
Several research analysts have weighed in on HTBX shares. Noble Financial reiterated a “buy” rating on shares of Heat Biologics in a report on Thursday, March 23rd. Zacks Investment Research raised Heat Biologics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research report on Friday, April 7th.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.